Rivaroxaban

Trending Medical and health breaking news Rivaroxaban as thromboprophylaxis improves clinical outcomes after COVID-19 hospitalization

Trending Medical and well being breaking information Rivaroxaban as thromboprophylaxis improves scientific outcomes after COVID-19 hospitalization

For patients at high risk for venous thromboembolism (VTE) discharged after COVID-19 hospitalization, thromboprophylaxis with rivaroxaban is associated with improved clinical outcomes, according to a study published online Dec. 15 in The Lancet. Eduardo Ramacciotti, M.D., from the Science Valley Research Institute in São Paulo, Brazil, and colleagues conducted a multicenter randomized trial involving patients…

Trending Medical and health breaking news Rivaroxaban Safely Cuts VTE Risk After COVID-19 Hospitalization

Trending Medical and well being breaking information Rivaroxaban Safely Cuts VTE Danger After COVID-19 Hospitalization

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Extended anticoagulation with low-dose rivaroxaban (Xarelto, Bayer/Janssen) after hospitalization for COVID-19 may reduce the risk of venous thromboembolism (VTE) without worsening the risk of bleeding in patients who had been considered high-risk for VTE, a multicenter randomized trial suggests. The primary…